Ligand activation of peroxisome proliferator-activated receptors (PPARs) prevents cardiomyocyte hypertrophy, but the underlying signalling mechanisms remain unknown. We previously reported that the anti-hypertrophic effect of the dietary polyunsaturated fatty acid, conjugated linoleic acid (CLA), was associated with the upregulation of diacylglycerol (DAG) kinase (DGK). DGK catalyses phosphorylative conversion/attenuation of DAG, thereby modulating protein kinase C (PKC) and G-protein signalling. As the anti-hypertrophic effects of CLA were attenuated by inhibitors of PPARs, the present aim was to investigate the involvement of DGK in the anti-hypertrophic actions of bona fide selective PPAR agonists.
Introduction
Cardiac hypertrophy is the increase in myocardial mass provoked by haemodynamic stress or myocardial injury. At the myocyte level, it is characterized by increases in cell size, protein synthesis, and changes in gene expression. 1 As hypertrophy leads to decompensation and heart failure, 2 -4 attenuation of hypertrophy is considered a promising therapeutic target to prevent cardiac failure. 5 There is evidence that peroxisome proliferator-activated receptors (PPARs) act as protective signals in hypertrophy. PPARs belong to the nuclear receptor family of transcription factors that regulate fatty acid and triglyceride metabolism. 6 All three isoforms are expressed in cardiomyocytes, 7, 8 and activation of PPARs a, 9 -11 b/d, 12 -14 or g 15 -17 prevents hypertrophy in response to mechanical strain or growth agonists such as endothelin-1 (ET1). 9 However, the anti-hypertrophic mechanisms invoked by PPARs remain poorly understood. The G aq protein-coupled receptor (GPCR) pathway, which includes diacylglycerol (DAG) and protein kinase C (PKC), plays a critical role in hypertrophy. 18, 19 GPCR ligands such as ET1 20 and angiotensin II 21 stimulate phospholipase C-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate to produce inositol trisphosphate and DAG. DAG kinases (DGKs) are intracellular lipid kinases that phosphorylate DAG to produce phosphatidic acid (PA). The resultant decrease in the availability of DAG attenuates translocation and activation of PKC, thereby terminating an arm of G protein signalling. Ten DGK isoforms have been identified in mammals, 22 but only three are found in cardiomyocytes: a, 1, and z. 23 The predominant isoform expressed in myocytes, DGKz, 23 reportedly plays a role in the regulation of cardiac hypertrophy. 24 -26 This study is predicated on our previous report on the ability of conjugated linoleic acid (CLA), a dietary polyunsaturated fatty acid, to suppress hypertrophy. 27 First, the anti-hypertrophic actions of CLA were blocked by inhibitors of PPARs a and g. Second, CLA upregulated DGKz expression and activity, and third, CLA attenuated ET1-induced activation of PKC1, a key pro-hypertrophic signal.
Although others have reported on the anti-hypertrophic properties of DGKz, 24 -26 a limitation of that initial report was that it did not demonstrate a 'causative' link between DGKz upregulation and the anti-hypertrophic actions of CLA. Nonetheless, those findings collectively led to conjecture that DGK may mediate the anti-hypertrophic actions of PPARs. We therefore address this remaining question by determining whether PPAR-DGK cross-talk occurs within the cardiomyocyte, and whether DGK contributes to the anti-hypertrophic actions of PPAR agonists.
Methods
See Supplementary material online for expanded methods and supplementary data.
Materials
ET1, troglitazone, fenofibrate, PA, and antibodies against sarcomeric a-actinin and b-actin were from Sigma-Aldrich (Oakville, Canada). DGKz, PPARa, and PPARg antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PKC1 antibody was from Millipore (Temecula, CA, USA). R59022 was from EMD Biosciences, Inc. (Gibbstown, NJ, USA). 21595 hBNP-luciferase was kindly provided by Dr David Gardner (University of California, San Francisco, CA, USA).
Cell culture of neonatal and adult rat cardiomyocytes
The study conforms to the Guide for the Care 
Transfection and luciferase assay
Myocytes were co-transfected with 21595 hBNP-luciferase and Renilla luciferase, as described previously. 27 
DGKz expression
To measure DGKz mRNA, real-time PCR was performed using primers for rat DGKz and normalized to GAPDH mRNA. DGKz protein was assayed by western blotting and normalized to b-actin, as described previously. 27 
PA formation
Cellular lipids were extracted, 31 and PA was measured using a previously described 32 fluorescence-based enzymatic assay. 
Lentiviral preparation and infection

Cell size
Myocyte size was assessed by immunofluorescent microscopy and computer-assisted planimetry, as described previously. 27 Each experiment consisted of 30 cells analysed per experimental group (n ¼ 3 -6).
Protein synthesis
[3H]-Leucine incorporation into acid-insoluble protein is a measure of protein synthesis that is commonly used as evidence of hypertrophy.
30
Four hours prior to harvesting, cells were pulsed with 1 mCi/mL [3H]-leucine.
[3H]-Leucine incorporation was measured as described previously. 27 Each experiment was done in triplicate.
Hypertrophic gene expression
Activation of the hypertrophic gene programme was assessed by real-time PCR to detect three foetal genes [brain natriuretic peptide (BNP), b-myosin heavy chain (bMHC), and skeletal muscle a-actin (SMaA)] that are usually only expressed in late embryonic and early neonatal life, but are reactivated during hypertrophic growth. We also examined a contractile protein gene expressed following exposure to hypertrophic stimuli [cardiac muscle a-actin (CMaA)]. 33 Hypertrophic gene mRNAs were normalized to GAPDH mRNAs.
PKC1 translocation
PKC1 levels were detected in soluble and particulate fractions of cell lysates by western blotting, as described previously. 27 
Statistics
n-Values are indicated in legends. Error bars represent SEMs. Data were subjected to one-way ANOVA and the Newman -Keuls multiple comparison test or unpaired Student's t-test, as appropriate.
Results
PPAR agonists upregulate DGKz
Selective ligands of PPARg (troglitazone) and PPARa (fenofibrate) upregulated DGKz mRNA and protein levels ( Figure 1 ). DGK activity was also increased by troglitazone and fenofibrate. Upregulation of DGKz was abolished by actinomycin D (20 mg/mL; Figure 2 ).
DGKz contributes to the anti-hypertrophic actions of PPARs
The involvement of DGK (all isoforms) was first assessed using the non-selective DGK inhibitor, R59022. ET1 increased BNP promoter activity, an indicator of hypertrophy, 34 and this was attenuated by troglitazone or fenofibrate ( Figure 3) . However, the ability of troglitazone or fenofibrate to prevent ET1-dependent BNP promoter activity was abolished by R59022. We next narrowed our query to the role of DGKz specifically, the predominant isoform in myocytes 23 and a regulator of hypertrophy. 24 -26 Targeted shRNA against DGKz achieved significant knockdown of DGKz to 12 + 1% vs. control ( Figure 4 ). ET1 induced increases in three indicators of hypertrophy ( Figure 4 , Table 1 ): myocyte size, [3H]-leucine incorporation, and hypertrophic gene expression, all of which were suppressed by troglitazone or fenofibrate. This ability of troglitazone or fenofibrate to prevent ET1-dependent hypertrophy was unaffected by nonsilencing control shRNA, but was abolished by shRNA knockdown of DGKz.
Suppression of pro-hypertrophic PKC1 signalling by PPARs involves DGKz
ET1 increased particulate:total PKC1, and this translocation of PKC1 to the particulate fraction was abolished by PPAR ligands ( Figure 5 ). The ability of PPAR ligands to prevent ET1-dependent PKC1 activation was unaffected by non-silencing control shRNA, but was abolished by shRNA knockdown of DGKz.
Anti-hypertrophic PPAR/DGK signalling in adult rat cardiomyocytes
Consistent with our findings in neonatal rat cardiomyocytes, ET1 increased the size of adult rat cardiomyocytes, and this cell growth was abolished by PPAR ligands ( Figure 6 ). Furthermore, the ability of DGKz mRNA and protein were assessed by real-time PCR and western blotting, respectively, and presented as per cent of normalized DGKz mRNA or protein vs. vehicle-treated controls. DGK activity was measured as PA formation. Troglitazone and fenofibrate increased (A and B) DGKz mRNA, (C and D) DGKz protein, and (E and F) DGK activity. n ¼ 3-4. *P , 0.05 and **P , 0.01 vs. vehicle-treated controls.
PPAR ligands to prevent ET1-dependent growth of adult myocytes was blocked by inhibition of DGK using R59022. Likewise, in adult rat myocytes, ET1 increased particulate:total PKC1, and this translocation of PKC1 to the particulate fraction was abolished by PPAR ligands ( Figure 6 ). The ability of PPAR ligands to prevent ET1-dependent PKC1 activation in adult myocytes was blocked by inhibition of DGK using R59022.
Discussion
These findings provide evidence that DGKz plays an important role in the anti-hypertrophic effects of PPARa and g ligands. We showed that blocking DGKz, whether using a non-selective chemical inhibitor of DGK or by knockdown of the DGKz isoform, abolishes the antihypertrophic effects of these PPARs. The ability of PPARa and g ligands to block PKC1, a key pro-hypertrophic signal, was also abrogated by DGKz knockdown, which is consistent with the mechanistic role of DGKz in terms of attenuating DAG levels.
This work is predicated on our previous report of the antihypertrophic actions of CLA, which we were able to attribute to the activation of PPARa and PPARg but not PPARb/d. 27 Thus, the present study highlights PPARs a and g. However, anti-hypertrophic properties have also been reported for PPARb/d, 12,14 although these other reports refer to the suppression of hypertrophy of neonatal rat cardiomyocytes elicited by angiotensin II or phenylephrine. To our knowledge, there is no evidence that PPAR b/d can prevent hypertrophy elicited by ET1. We conducted preliminary experiments to assess a possible role for DGK in the growth-inhibitory effects of PPARb/d (see Supplementary material online). In the context of ET1-dependent hypertrophy, the selective PPARb/d agonist, GW501516, exerts a partial, but statistically significant, attenuating effect. The ability of GW501516 to partially attenuate ET1-induced hypertrophy is abolished by R59022 (DGK inhibitor). In addition, we found that GW501516 also increased expression of DGKz. Therefore, the role that DGKz plays in the growth-inhibitory effects of PPARs likely extends to the anti-hypertrophic actions of PPbARb/d, a possibility that warrants further study.
Work by others has led to the suggestion that the antihypertrophic actions of PPARa might be related to the suppression of AP-1 DNA-binding activity, 10 since ET1-induced PKC1 signalling leads to the activation of the AP-1 transcription factor. 24, 35 Our data are consistent with this notion, since forced overexpression of DGKz in cardiomyocytes blocks not only ET1-dependent hypertrophy, but also AP-1 signalling. 24 Combined with our data showing first, that PPARs increase DGKz expression, and second, that DGKz ET1-treated cells.
PPARs a and g suppress hypertrophy via DGKz mediates the anti-hypertrophic effects of PPARs, it is conceivable that PPAR-DGKz crosstalk, by leading to depletion of DAG, abrogates stimulation of pro-hypertrophic PKC1/AP-1 signalling by ET1.
Of the three DGK isoforms found in myocytes, a, 1, and z, 23 antihypertrophic activity has so far been linked only to DGK1 and DGKz. DGKz overexpression blocked ET1-induced hypertrophy of cultured myocytes, 24 and in vivo, cardiac-restricted overexpression of DGKz in mice blocked angiotensin II-and phenylephrine-induced hypertrophy. 25 Expression of DGK1 mRNA in the left ventricular myocardium is reduced in aortic-banded vs. sham rats. 36 Cardiac-specific overexpression of DGK1 in mice also prevented hypertrophy in response to phenylephrine or pressure overload. 37 Our experiments focused on DGKz because it is the predominant isoform expressed in myocytes. 23 Given that upregulation of DGKz by troglitazone and fenofibrate was abolished by the transcriptional inhibitor, actinomycin D (Figure 2) , and that PPARs can signal as nuclear receptor transcription factors, 6 one possibility is direct binding of PPARs to the DGKz gene promoter. Although the PPRE consensus sequence does not appear in the DGKz gene promoter, this does not necessarily preclude direct binding of PPARs. Nakachi et al. 38 detected 167 gene promoters with strict PPARg binding during adipocyte differentiation in 3T3-L1 cells, yet PPRE consensus sequences were present in only 15 of these target genes. Three of these genes were activated by PPARg, lack consensus PPREs, and instead contain imperfect or atypical PPREs that vary in the binding site and/or spacer sequences. 39 PPARs might also regulate the DGKz promoter indirectly through complex formation with other transcription factors such as Sp1. The DGKz promoter contains Sp1 sites, and PPAR-dependent modulation of numerous genes involves Sp1. 40 -43 Whatever the proximal signalling mechanism, the nature of the putative interaction between PPARs and the DGKz promoter requires further study. Our finding that DGKz mediates the ability of PPARs to suppress PKC1 activity is noteworthy, since PKC1 is considered to be a key effector of hypertrophy in the cardiomyocyte. 44 Of the six PKC isoforms found in myocytes, 45 only PKC1 dramatically translocates to the membrane fraction following hypertrophic stimuli such as pressure overload in vivo 46 and ET1 in vitro. 47 -50 Also, mice overexpressing constitutively active PKC1 develop hypertrophy. 51, 52 Notably, the anti-hypertrophic actions of DGKz have been linked with the inhibition of PKC1. Both in vitro and in vivo studies implicated termination of PKC1 signalling vis-à-vis depletion of DAG levels as the mechanism that underpins blockade of hypertrophy by DGKz overexpression. 24, 25 Our data imply that upregulation of DGKz is rapid and possibly transient. levels, leading to a sustained increase that was statistically detectable by 2 h. It is important to note, however, that the rapid/transient nature of DGKz upregulation is not inconsistent with the mechanistic role of DGKz that we propose. Binding of ET1 to the ET A receptor causes a conformational change that favours activation of phosphoinositide-specific phospholipase C-b (PLCb). PLCb in turn hydrolyses phosphatidylinositol-4 ′ ,5 ′ -bisphosphate, thereby generating DAG and IP3. This occurs within seconds. 53, 54 Virtually immediately, as sarcolemmal DAG increases, PKC1 translocates from the soluble to the membrane fraction, where it is activated by binding of DAG. 54 DAG-dependent translocation of PKC1 is detectable within minutes by immunoblotting 55 and two-photon microscopy. 56 Although the distribution of PKC1 to the membrane fraction by ET1 is only sustained for a matter of minutes, 55 activated PKC1
initiates signalling cascades that collectively confer the hypertrophic response to ET1. Target downstream effectors include small G proteins such as Ras, and Ras-dependent extracellular-signal-regulated kinases (ERKs), 57 which is important particularly since Marshall et al. 58 recently report that ERK1/2 regulates the majority of genes involved in the early stages of cardiomyocyte hypertrophy. Therefore, if signalling by ET1 is disrupted at a pivotal, early point such as PKC1 activation, this might have numerous downstream effects that will collectively prevent the hypertrophic response. Here, we show that despite the rapid and/or transient nature of PPAR-induced upregulation of DGKz, it occurs during a window of time when PKC1 activation is indeed being suppressed, such that the hypertrophic response per se (cell size augmentation, protein synthesis, and hypertrophic gene expression) is ultimately blocked. PPARs a and g suppress hypertrophy via DGKz It bears mentioning that, by inhibiting PKC1 activation in ET1-treated myocytes, PPAR-DGKz signalling might be modulating ERK activity. A role for the ERK cascade in the hypertrophic response of cardiomyocytes was proposed over a decade ago. 59 Numerous hypertrophic stimuli activate ERK, including ET1 60,61 and mechanical strain, 61 and disrupting ERK signalling abrogates the hypertrophic response to ET1 and isoproterenol. 62 T-cells derived from DGKz-deficient mice exhibit aberrant augmentation of both ERK activation and cell proliferation. 63 This suggests that, at least in T-cells, DGKz acts as an endogenous inhibitor of pro-growth ERK signalling. We know that in cardiomyocytes, PKC1 participates in the activation of the ERK cascade by ET1, 54 and we have shown that DGKz suppresses PKC1 signalling. Thus, it is possible that at least part of the anti-hypertrophic effect of PPARs involves downstream suppression of ERK, via DGKz-dependent inhibition of PKC1. Indeed, we found that the ability of ET1 to activate ERK in cardiomyocytes is attenuated, at least in part, by troglitazone and fenofibrate, and again, this attenuation occurs in a DGK-dependent manner (see Supplementary material online). DGK-mediated phosphorylation of DAG leads to the generation of PA, which is known to trigger hypertrophic processes such as protein synthesis 64, 65 and activation of mitogen-activated protein (MAP)
kinases. 64 However, DGK is only a minor contributor; most PA is actually generated through the hydrolysis of phosphatidylcholine by phospholipase D. 24 Thus, overexpression of DGK 24 or PPARdependent upregulation of DGK probably contributes only negligibly to the pool of PA and its signalling potential. 24 The ability of troglitazone and fenofibrate to suppress ERK activity (see Supplementary material online) supports this notion since, in contrast, PA activates MAP kinases. 64 Thus, the growth-inhibitory effects of liganded PPARa and g are more consistent with the ability of DGK to suppress PKC1 via depletion of DAG rather than the ability of DGK to generate PA. ET1 elicited an 7-fold increase in PKC1 translocation in neonatal myocytes vs. only an 1.75-fold increase in adult myocytes ( Figure 6 ). This might be due to inherent differences between neonatal and adult myocytes. For example, ET1 stimulated phosphorylation of myristoylated, alanine-rich protein kinase C substrate (MARCKS) 66 as well as praline-rich tyrosine kinase (PYK2). 67 Both of these events were PKC1 dependent, 66, 68 and they occurred in neonatal and adult myocytes. However, similar to our findings, the magnitude of these ET1/ PKC1-dependent responses is smaller in adult myocytes than in neonatal myocytes. Varying experimental conditions might also play a role. We synchronize cultured myocytes by serum deprivation in neonatal myocytes (0.5% serum) and serum starvation in adult myocytes (0% serum). However, although lack of exposure to serum might limit the degree to which ET1 activates PKC1 in adult myocytes, the magnitude of the response is consistent with that reported by Pucéat et al. 47 Thus, despite these minor discrepancies, the important points remain that in both adult and neonatal myocytes, (i) ET1 increases PKC1 translocation, (ii) PPAR agonists attenuate ET1-induced PKC1 activation, and (iii) inhibitory effects of PPAR agonists depend on DGK activity, based on the ability of R59022 to restore ET1-dependent induction of PKC1. It also bears noting that in adult myocytes, ET1-induced PKC1 translocation appeared to be limited in part by R59022 treatment. This trend was not statistically significant, although it might have contributed somewhat to the ability of R59022 to restore ET1-dependent PKC1 activation in the presence of PPAR agonists.
The present study shows for the first time that, in cardiomyocytes, DGKz plays a pivotal role in the ability of PPARs to attenuate hypertrophy, at least in response to ET1. The mechanistic contribution of DGKz is likely due to the attenuation of PKC1 signalling by depleting its substrate, DAG. Since PPAR/DGKz crosstalk leads to the attenuation of DAG-PKC1 signalling, an early signalling event in myocyte hypertrophy, PPAR ligands block multiple components of the hypertrophic response to ET1, including myocyte growth, de novo protein synthesis, and activation of hypertrophic genes. Taken in context with other studies on DGKz, interventions that target PPAR/DGKz signalling might represent a novel therapeutic approach to address the problem of cardiac hypertrophy.
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